New drug cocktail aims to fight tough pancreatic cancer
NCT ID NCT06313970
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 40 times
Summary
This Phase 2 trial is testing an experimental immunotherapy drug called QL1706 combined with standard chemotherapy (nab-paclitaxel and gemcitabine), with or without another drug called bevacizumab, as a first treatment for people with advanced pancreatic cancer that cannot be removed by surgery. The study will enroll 58 participants in China to see if the combination can shrink tumors and control the disease. Researchers are also monitoring safety and how long any benefits last.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QL1706 (an experimental immunotherapy drug) plus nab-paclitaxel, gemcitabine, and optionally bevacizumab
What this could lead to
If successful, this could point toward a more effective first-line treatment for advanced pancreatic cancer, potentially shrinking tumors and extending life.
What could go wrong
This is an early Phase 2 exploratory study with only 58 participants, so results may not apply broadly. The drug combination may cause significant side effects, and there is no guarantee it will work better than current treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.